Loading stock data…
VIR
$10.00-0.21 (-2.10%)
Market ClosedLast close May 1
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vir Biotechnology, Inc. in the Healthcare sector is trading at $10.00. The stock is currently 14% below its 52-week high of $11.66, remaining 47.7% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why VIR maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.00
Potential Upside
5%
Whystock Fair Value$10.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$20.78+107.8%
Range$17.00 – $30.00
Fundamentals
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.90%
Volume
Today's trading volume
1.01M
Recent News
Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration
On April 16, 2026, Vir Biotechnology, Inc. announced the closing of its global collaboration and licensing agreement with Astellas for VIR-5500 in metastatic prostate cancer, securing a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 per share, a near-term US$20,000,000 milestone, potential further milestones up to US$1.37 billions, and a 50/50 U.S. profit and loss split, while a separate arbitration was initiated by Brii Biosciences over alleged breaches...
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.’s share was trading at $11.09 as of April 20th. VIR’s trailing P/E was 5.92 according to Yahoo Finance. Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers […]
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnology announced the closing of its global collaboration and licensing agreement with Astellas following the expiration of the […]
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that it had dosed the first patient in one of three dose-expansion cohorts in its ongoing Phase 1 trial of VIR-5500. VIR-5500 is an investigational treatment for metastatic prostate cancer. VIR-5500 is a […]
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the best low priced biotech stocks to invest in. On April 13, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that the first patient had been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for […]